88448
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 8
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -5.737783223
- umap2_2d
- 0.004455329
- umap1_3d
- 0.84274561
- umap2_3d
- 2.97203696
- umap3_3d
- -0.083168926
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.280
- KRAS_SIGNALING_DN+0.200
- NOTCH_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- APICAL_SURFACE+0.180
- BILE_ACID_METABOLISM+0.030
- ESTROGEN_RESPONSE_EARLY+0.020
- ESTROGEN_RESPONSE_LATE-0.020
- APICAL_JUNCTION-0.040
Top 10 suppressed
- MYC_TARGETS_V1-0.550
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.520
- E2F_TARGETS-0.500
- MTORC1_SIGNALING-0.450
- G2M_CHECKPOINT-0.430
- CHOLESTEROL_HOMEOSTASIS-0.420
- MYC_TARGETS_V2-0.420
- OXIDATIVE_PHOSPHORYLATION-0.410
- PROTEIN_SECRETION-0.410
- GLYCOLYSIS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02146 | — | cohortA1 | 0.878 |
| 2 | SRR4195656 | — | — | 0.871 |
| 3 | TCGA-LD-A7W6-01A-81R-A352-07 | — | A | 0.871 |
| 4 | SRR2755094 | — | — | 0.862 |
| 5 | SRR8526730 | — | cohortA1 | 0.852 |
| 6 | MNG904 | — | — | 0.848 |
| 7 | SRR11296732 | — | — | 0.848 |
| 8 | TCGA-NJ-A55A-01A-11R-A262-07 | — | cohortA1 | 0.847 |
| 9 | X65f5effa.07f7.4ed3.9e0a.3a0d9d451474 | — | cohortA1 | 0.844 |
| 10 | TCGA-MP-A4T6-01A-32R-A262-07 | — | cohortA1 | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |